Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1056/NEJMc2211320 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Adenoviral-vectored neoantigen vaccine augments hyperexpanded CD8 T cell control of tumor challenge in mice.
J Immunother Cancer
December 2024
Harvard Medical School, Boston, Massachusetts, USA
Background: Neoantigens are promising immunogens for cancer vaccines and are often delivered as adjuvanted peptide vaccines. Adenoviral (Ad) vectors have been shown to induce strong CD8 T cell responses as vaccines against SARS-CoV-2, Ebola, and Zika, but their utility as neoantigen delivery vectors remains largely unexplored. In this study, we examine how an Ad-vectored neoantigen vaccine would impact tumor immunity compared with a peptide neoantigen vaccine.
View Article and Find Full Text PDFConsumption of antimicrobials for use in food-producing animals in New Zealand, a measure of progress in reduction from 2015 to 2022.
N Z Vet J
December 2024
Ethical Agents, Manukau, New Zealand.
Aims: To describe progress in the reduction of the consumption of antimicrobial drugs by food-producing animals in New Zealand to 2022 and to identify the animal production sectors where progress has been greatest, and those where opportunities remain.
Methods: Data were sourced from official government and industry reports to update previous estimates of consumption (as sales) of antimicrobial products applied to food-producing animals in New Zealand, European countries and the USA. Antimicrobial consumption (AMC) was estimated based on the amount of active ingredient sold, per kg of animal biomass standardised to the probable weight at time of treatment or lifetime mean weight but not slaughter weight (population correction unit; PCU).
High resistance barrier and prophylactic protection in preclinical models of SARS-CoV-2 with two siRNA combination.
Nucleic Acids Res
December 2024
Alnylam Pharmaceuticals; Cambridge, MA 002142, USA.
RNA interference is a natural antiviral mechanism that could be harnessed to combat SARS-CoV-2 infection by targeting and destroying the viral RNA. We identified potent lipophilic small interfering RNA (siRNA) conjugates targeting highly conserved regions of SARS-CoV-2 outside of the spike-encoding region capable of achieving ≥3-log viral reduction. Serial passaging studies demonstrated that a two-siRNA combination prevented development of resistance compared to a single siRNA approach.
View Article and Find Full Text PDFRSM01, a novel respiratory syncytial virus monoclonal antibody: preclinical characterization and results of a first-in-human, randomised clinical trial.
BMC Infect Dis
December 2024
Bill & Melinda Gates Medical Research Institute, Cambridge, MA, USA.
Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract disease among infants and young children worldwide, especially in low- and middle-income countries (LMICs). RSM01 is a novel, highly potent, half-life-extended anti-RSV monoclonal antibody (mAb) candidate primarily being developed for LMICs. Here we present the preclinical characterisation and results of a phase 1 trial of RSM01.
View Article and Find Full Text PDFCATHETER II: a randomised controlled trial comparing the clinical effectiveness of various washout policies versus no washout policy in preventing catheter-associated complications in adults living with long-term catheters.
BMJ Open
December 2024
Centre for Healthcare Randomised Trials, University of Aberdeen, Aberdeen, UK.
Objectives: Do weekly prophylactic saline or acidic catheter washouts in addition to standard long-term catheter (LTC) care improve the outcomes of adults with LTC compared with standard LTC care only.
Design: Three-arm superiority open-label randomised controlled trial.
Setting: UK community-based study.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!